Condensed Consolidated Statements of Loss and Comprehensive Loss - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue		$ 9,954	$ 12,192
Operating expenses:
Research and development	[1]	39,287	52,647
Sales and marketing	[1]	3,365	3,771
General and administrative	[1]	17,352	15,134
Depreciation and amortization		4,844	5,514
Total operating expenses		64,848	77,066
Loss from operations		(54,894)	(64,874)
Other (income) expense
Interest income		(10,401)	(9,759)
Grants and incentives		(3,275)	(3,374)
Other		1,529	(3,593)
Total other (income)		(12,147)	(16,726)
Net loss before income tax		(42,747)	(48,148)
Income tax recovery		(2,137)	(8,038)
Net loss		(40,610)	(40,110)
Foreign currency translation adjustment		(96)	(630)
Comprehensive loss		$ (40,706)	$ (40,740)
Net loss per share
Basic (USD per share)		$ (0.14)	$ (0.14)
Diluted (USD per share)		$ (0.14)	$ (0.14)
Weighted-average common shares outstanding
Basic (in shares)		292,723,901	287,767,136
Diluted (in shares)		292,723,901	287,767,136
Research fees
Revenue:
Total revenue		$ 9,774	$ 10,570
Licensing revenue
Revenue:
Total revenue		180	372
Milestone payments
Revenue:
Total revenue		$ 0	$ 1,250

[1] Exclusive of depreciation and amortization